Cost-effectiveness of an intervention to increase cancer screening in primary care settings

被引:24
|
作者
Chirikos, TN
Christman, LK
Hunter, S
Roetzheim, RG
机构
[1] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[2] Univ S Florida, Dept Family Med, Tampa, FL 33612 USA
关键词
cost-effectiveness analysis; cancer screening; mammography; PAP smears; fecal occult blood tests; health disparities;
D O I
10.1016/j.ypmed.2004.03.021
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. The main goal was to conduct a cost-effectiveness analysis of an intervention designed to increase cancer screening rates in primary care settings serving disadvantaged populations. The Cancer Screening Office Systems intervention reminded clinicians whether screening mammography, Pap smears, and/or fecal occult blood tests were up-to-date in eligible patients and then established a division of office responsibilities to ensure that tests were ordered and completed. Methods. The cost-effectiveness analysis was predicated on data generated from a cluster-randomized controlled trial of Cancer Screening Office Systems conducted at eight clinics participating in a county-funded health insurance plan in Florida. Cost numerators were computed from estimated time inputs of both clinical personnel and patients valued at nationally representative wages as well as expenses for Cancer Screening Office Systems-related materials and overhead. Effectiveness denominators were constructed from net changes in screening rates observed experimentally over a 12-month follow-up. Two types of incremental cost-effectiveness ratios were computed: the cost per extra screening test by type and the cost per life-year saved without and with Cancer Screening Office Systems. Results. Cancer Screening Office Systems produced statistically significant increases in screening rates, and these gains more than outweighed the costs of the intervention viewed from either payer or societal perspectives. Conclusions. Cancer Screening Office Systems are a cost-effective means of addressing cancer-related health disparities. (C) 2004 The Institute For Cancer Prevention and Elsevier Inc. All rights reserved.
引用
收藏
页码:230 / 238
页数:9
相关论文
共 50 条
  • [41] Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care
    M. Y. Bertram
    S. S. Lim
    J. J. Barendregt
    T. Vos
    Diabetologia, 2010, 53 : 875 - 881
  • [42] Cost-effectiveness of liver cancer screening
    Cucchetti, Alessandro
    Cescon, Matteo
    Erroi, Virginia
    Pinna, Antonio D.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2013, 27 (06) : 961 - 972
  • [43] Cost-effectiveness of screening for bowel cancer
    Bolin, Terry D.
    Korman, Melvyn G.
    Nicholson, Fiona
    Pezzullo, Lynne
    Engelman, Jeffrey
    Collings, Katherine
    Creelman, David Gilchrist
    MEDICAL JOURNAL OF AUSTRALIA, 2016, 204 (01) : 11 - 13
  • [44] Cost-effectiveness of colorectal cancer screening
    Glick, SN
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (04): : 407 - 408
  • [45] The cost-effectiveness of screening for colorectal cancer
    Telford, Jennifer J.
    Levy, Adrian R.
    Sambrook, Jennifer C.
    Zou, Denise
    Enns, Robert A.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2010, 182 (12) : 1307 - 1313
  • [46] COST-EFFECTIVENESS OF COLON CANCER SCREENING
    LIEBERMAN, D
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1991, 86 (12): : 1789 - 1794
  • [47] Cost-effectiveness of colorectal cancer screening
    McMahon, PM
    Bosch, JL
    Gleason, S
    Halpern, EF
    Lester, JS
    Gazelle, GS
    RADIOLOGY, 2001, 219 (01) : 44 - 50
  • [48] Cost-effectiveness of cervical cancer screening
    Goldie, Sue J.
    Kim, Jane J.
    Myers, Evan
    VACCINE, 2006, 24 : 164 - 170
  • [49] Cost-effectiveness analysis of artificial intelligence-based diabetic retinopathy screening in Australian primary care settings.
    Hu, Wenyi
    Zhu, Zhuoting
    He, Mingguang
    Zhang, Lei
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [50] Cost-effectiveness of ColoSTAT for primary colorectal cancer screening in the United States
    He, Emily
    Deak, Elena
    Schmitt, Laetitia Helene Marie
    Alesso, Sonia Maria
    Gilbert, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)